Open AccessEffect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
Author(s) -
Donald P. Tashkin,
Ayca Ozol-Godfrey,
Sanjay Sharma,
Shahin Sanjar
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s304182
Subject(s) - medicine , copd , placebo , chronic bronchitis , glycopyrrolate , adverse effect , bronchodilator , bronchitis , quality of life (healthcare) , incidence (geometry) , anesthesia , physical therapy , asthma , atropine , alternative medicine , nursing , physics , pathology , optics
Chronic bronchitis (CB) is one of the conditions that contribute to chronic obstructive pulmonary disease (COPD). Despite its widespread prevalence among patients with COPD and overall negative impact on treatment outcomes, the effect of CB on the efficacy of bronchodilator therapy has not been evaluated. The objective of this post hoc analysis is to assess the effect of nebulized glycopyrrolate (GLY) on lung function and health-related quality of life outcomes in patients with St George's Respiratory Questionnaire (SGRQ)-defined CB at baseline.